AstraZeneca's (AZN) - Get Report phase 3 trial of a Covid-19 vaccine being developed with the University of Oxford has shown promising results in inducing a positive immune response - a sign that a vaccine could be ready to ship out to the public before the end of the year.
Citing unnamed sources, both the Financial Times and Reuters reported on Monday that the British pharmaceutical giant’s most recent findings related to its phase 3 trial show that the vaccine candidate triggers protective antibodies and T-cells, helping the body fight off the virus.
Adverse responses to the vaccine among the elderly - the age group at highest risk from the coronavirus - also were found to be lower, according to both news organizations. Details of the findings are expected to be published shortly in a clinical journal, according to the Financial Times.
The reports come as countries in the northern hemisphere face a “dangerous moment,” as U.S. coronavirus infections hit a record for the second day and France’s cases rose by more than 50,000.
AstraZeneca in August kicked off Phase 3 testing of its Covid-19 trial vaccine, which involves some 30,000 participants in the U.S. as well as in the U.K., Brazil and South Africa. However, the trial was halted earlier this month after one of the trial patients became ill, triggering a wider review of the program.
The U.S. Food and Drug Administration said on Friday that AstraZeneca can resume the study in the U.S. The U.K trial has already been resumed.
Latest Videos From TheStreet and Jim Cramer:
- Jim Cramer Says Earnings Pinpoint Stocks to Buy With or Without Stimulus
- PPE and Your Portfolio: Inside a Disruptive Industry
- PPE in the Ring: How O2 Industries Partnered With UFC
- PPE and the Supply Chain: How O2 Industries Adapted During Pandemic
- Coronavirus: The Latest Numbers on the COVID-19 Pandemic
- How Much Do World Series Tickets Cost in 2020?
- How to Protect Your Portfolio for Any Election Outcome